Facts About XARELTO®
Renal function information
Renal Function (CrCl)
Mild (>50-79 mL/min)1,2
Moderate (30-50 mL/min)1,2
Severe (15-29 mL/min)2
End-stage renal disease (ESRD) (<15 mL/min)3
CrCl = creatinine clearance.
Renal dosing considerations
- Nonvalvular AF: Periodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly. Consider dose adjustment or discontinuation of XARELTO® in patients who develop acute renal failure while on XARELTO®
- All other indications: Avoid using XARELTO® in patients with CrCl <30 mL/min
Aspects of treatment with XARELTO® and warfarin
There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
*Meta-analysis assessed 8 studies, including a total of 14 groups involving 22,237 warfarin-treated AF patients, with 41,199 years of follow-up. AF patients in the 14 groups spent 55% (95% CI: 51%-58%) of their time within the therapeutic INR range.11
AF = atrial fibrillation; INR = international normalized ratio; PT = prothrombin time.